Clinical Trial: Rozanolixizumab for MOG Antibody-associated Disease (NCT05063162)

1106. CosMOG - Clinical Trial for MOGAD TreatmentПодробнее

NEW Treatment for MOG Antibody Disease? Rozanolixizumab MOGAD TrailПодробнее

Research developments in MOGADПодробнее

The BEST MOG Antibody Disease (MOGAD) Support Groups - Updated for 2023!Подробнее

2023 RNDS | Clinical trials in MOGAD, NMOSD, and moreПодробнее

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)Подробнее

2022 RNDS | Learn about new clinical trials in MOGADПодробнее

cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGADПодробнее

2022 Pre-RNDS | MOG Antibody Disease (MOGAD)Подробнее

Are You Missing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease (MOGAD)?Подробнее

2021 RNDS | Understanding MOG and AQP-4 antibody testingПодробнее

2021 RNDS | MOG Antibody Disease (MOGAD)Подробнее

2021 RNDS | How do you get a diagnosis of ADEM, AFM, MOGAD, NMOSD, ON, and TM?Подробнее

Michael on Meteoroid for MOGAD: Understanding the Satralizumab Clinical TrialПодробнее

Module 7 – Case Study 2: Model-Informed Clinical Development of MosunetuzumabПодробнее

2024 RNDS | NMOSD and MOGAD Clinical TrialsПодробнее

912. MOG Antibody Disease: Diagnosis and Treatment GuidelinesПодробнее

Proposed criteria for the diagnosis of MOGADПодробнее

MOG AD Diagnosis: Testing and TitersПодробнее